Follow
Joaquim Bosch-Barrera (ORCID:0000-0002-0893-7821)
Joaquim Bosch-Barrera (ORCID:0000-0002-0893-7821)
Catalan Institute of Oncology (ICO). University of Girona (UdG). IDIBGI-CERCA
Verified email at iconcologia.net - Homepage
Title
Cited by
Cited by
Year
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ...
The Lancet Oncology 19 (4), 521-536, 2018
5532018
Metformin: multi-faceted protection against cancer
S Del Barco, A Vazquez-Martin, S Cufí, C Oliveras-Ferraros, ...
Oncotarget 2 (12), 896, 2011
3832011
STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis
N Priego, L Zhu, C Monteiro, M Mulders, D Wasilewski, W Bindeman, ...
Nature Medicine 24 (7), 1024-1035, 2018
3472018
Metformin-induced preferential killing of breast cancer initiating CD44+ CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast …
S Cufí, B Corominas-Faja, A Vazquez-Martin, C Oliveras-Ferraros, ...
Oncotarget 3 (4), 395, 2012
1672012
Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy
J Bosch-Barrera, JA Menendez
Cancer treatment reviews 41 (6), 540-546, 2015
1652015
Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer
M Provencio, E Nadal, JL González-Larriba, A Martínez-Martí, R Bernabé, ...
New England Journal of Medicine 389 (6), 504-513, 2023
1522023
Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
S Verdura, E Cuyàs, E Cortada, J Brunet, E Lopez-Bonet, ...
Aging (Albany NY) 12 (1), 8, 2020
1202020
Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells
B Corominas-Faja, E Cuyàs, J Gumuzio, J Bosch-Barrera, O Leis, ...
Oncotarget 5 (18), 8306, 2014
1152014
Targeting STAT3 with silibinin to improve cancer therapeutics
J Bosch-Barrera, B Queralt, JA Menendez
Cancer treatment reviews 58, 61-69, 2017
1032017
Metformin is a direct SIRT1-activating compound: computational modeling and experimental validation
E Cuyàs, S Verdura, L Llorach-Parés, S Fernández-Arroyo, J Joven, ...
Frontiers in endocrinology 9, 657, 2018
1022018
Stem cell-like ALDHbright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the …
B Corominas-Faja, C Oliveras-Ferraros, E Cuyas, A Segura-Carretero, ...
Cell cycle 12 (21), 3390-3404, 2013
952013
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
A Vazquez-Martin, S Cufí, C Oliveras-Ferraros, VZ Torres-Garcia, ...
Scientific reports 3 (1), 1-15, 2013
952013
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells
P Muñoz-Guardiola, J Casas, E Megías-Roda, S Solé, H Perez-Montoyo, ...
Autophagy 17 (6), 1349-1366, 2021
832021
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
S Cufí, R Bonavia, A Vazquez-Martin, C Oliveras-Ferraros, ...
Scientific reports 3 (1), 2459, 2013
772013
Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
S Cufi, A Vazquez-Martin, C Oliveras-Ferraros, R Quirantes, ...
Cell cycle 11 (6), 1235-1246, 2012
762012
Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR …
S Cufí, R Bonavia, A Vazquez-Martin, B Corominas-Faja, ...
Food and chemical toxicology 60, 360-368, 2013
742013
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
N Karachaliou, J Codony-Servat, C Teixidó, S Pilotto, A Drozdowskyj, ...
Scientific reports 5 (1), 17499, 2015
722015
Silibinin is a direct inhibitor of STAT3
S Verdura, E Cuyàs, L Llorach-Parés, A Pérez-Sánchez, V Micol, ...
Food and Chemical Toxicology 116, 161-172, 2018
702018
STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer
E Cuyas, A Pérez-Sánchez, V Micol, JA Menendez, J Bosch-Barrera
Cell Cycle 15 (24), 3413-3418, 2016
672016
Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)
M Provencio, E Carcereny, D Rodríguez-Abreu, R López-Castro, ...
Translational lung cancer research 8 (4), 461, 2019
632019
The system can't perform the operation now. Try again later.
Articles 1–20